Statin use and prostate cancer risk.

J. Shannon,M. Garzotto,A. Palma
DOI: https://doi.org/10.1200/JCO.2004.22.14_SUPPL.4596
IF: 45.3
2004-07-15
Journal of Clinical Oncology
Abstract:4596 Background: One in seven men over age 60 will be diagnosed with prostate cancer. Improvements in screening and diagnostic procedures allow clinicians to better identify men at high risk of having prostate disease, but no established means of preventing prostate cancer are currently available. Statins are a group of drugs used to control high cholesterol through inhibiting HMG CoA reductase and interfering in the mevalonate pathway. Recent research has demonstrated that in a number of tumor types, statins also induce apoptosis and growth arrest. The purpose of this pilot study was to evaluate the association between statin use and prostate cancer risk in a population of older veterans enrolled in a case-control study of diet and prostate cancer risk. METHODS Cases were recruited upon referral for prostate biopsy and frequency age-matched; PSA normal controls were identified from the VA primary care clinic. Statin use was determined from medical record review. Years of use, type of statin, dose and any changes were recorded. Years of use were categorized as > or <= 3 years of use of any single or combined statin. Dose was categorized as > or <= 40mg/day, based on the highest dose prescribed. RESULTS Records from 47 incident prostate cancer cases and 142 PSA normal clinic controls were reviewed. After adjusting for age and body mass index, men with any recorded statin use had a 56% lower risk of prostate cancer as opposed to non-users (odds ratio (OR) 0.44, 95% confidence interval (CI) (0.22-0.88)). When statin use was grouped by duration and dose, those with the longer duration of use (>3 years) and higher dose (>40mg/day) were at lower risk of prostate cancer as compared to non-users (OR=0.35, 95% CI=0.12-1.00). CONCLUSIONS Results of this pilot study suggest that any statin use is associated with a reduced risk of prostate cancer and that use for a longer period of time at a higher dose may confer the most risk reduction. This study is limited by a small sample size and lack of control for additional comorbid factors. If these results are confirmed in a larger prospective study they may provide necessary evidence to consider the use of statin drugs in prostate cancer prevention. No significant financial relationships to disclose.
What problem does this paper attempt to address?